Puberty blockers are medications that stop the body from producing oestrogen and testosterone. In the clinic, they’re called gonadotropin-releasing hormone agonists (GnRHa).
If adolescents take these medications during puberty, bodily changes associated with puberty are prevented. If these medications are stopped, these bodily changes resume.
Puberty blockers have been used since the early 1980s to treat early-onset puberty in young children.
Beginning in the 1990s, puberty blockers have also been used in transgender adolescents to help prevent the unwanted development of masculinising or feminising physical changes that occur during puberty.
What are the benefits for transgender adolescents?
Many transgender children describe anxiety about unwanted physical changes that will occur because of puberty, especially as adolescence approaches.
For those presumed female at birth, these unwanted changes include breast development and starting periods. For those presumed male at birth, these unwanted changes may include the development of a deeper voice, an Adam’s apple, facial hair and a masculine physique.
Many of these physical changes are irreversible and result not only in gender dysphoria but also misgendering. This is when transgender people are mistakenly assumed to be the gender they were presumed at birth. Misgendering can be a significant and lifelong source of distress.
Some transgender people will seek out surgery to address these unwanted irreversible changes. This might be to masculinise their chest, feminise their face, alter their voice, or reduce their Adam’s apple.
For transgender young people and their families, the most obvious benefits of puberty blockers are to avoid unwanted changes that come with puberty. It can also reduce misgendering and prevent the need for future surgery.
Several studies have assessed the potential benefits of puberty blockers. A 2024 systematic review of the research found consistent evidence showing they effectively suppressed puberty.
The study the review authors identified as being the highest quality found significantly improved psychological outcomes. Puberty blockers reduced suicidal thoughts and actions in transgender adolescents compared to those who had not accessed the treatment.
When should puberty blockers be started?
Puberty blockers can only be started once puberty has commenced. The age at which this occurs varies considerably between individuals. To avoid unwanted physical changes, puberty blockers should ideally begin in early to mid-puberty.
However, many transgender adolescents have been started on puberty blockers in late puberty or even after puberty has finished.
In England, for example, at least 12 months of puberty-blocker treatment was previously mandatory for any transgender adolescent under 18 who wished to access oestrogen or testosterone. This resulted in many young people starting puberty blockers well after their puberty was complete.
One potential problem with commencing puberty blockers beyond early or mid-puberty is that unwanted physical changes have already occurred, so many benefits of this treatment are no longer expected to occur.
The recent systematic review on puberty blockers noted that, while many studies saw improvements in psychological wellbeing, others failed to observe a difference. One possible explanation is that none of these studies accounted for the stage of puberty at which treatment was commenced.
Notably, a more recent study from Harvard University confined the analysis to treatment with puberty blockers in early to mid puberty. It found treatment was associated with significant reductions in anxiety, depression and suicidal thoughts.
Risks of puberty blockers for transgender adolescents
Puberty blockers are generally well-tolerated. But as with any medical intervention, they can also cause unwanted effects. This includes reductions in bone density and fertility, and changes in adult height.
When started beyond early to mid puberty, they are more likely to cause menopausal-like side effects, such as hot flashes. This is due to a reduction in sex hormone production.
There are also potential long-term effects of puberty blockers that are still being investigated.
Brains mature substantially during adolescence. But it remains unclear what effect puberty blockers may have on cognitive development. While the use of puberty blockers in early-onset puberty has not been shown to affect cognitive functioning, studies in transgender adolescents are ongoing.
Where are the randomised controlled trials of puberty blockers?
Randomised controlled trials are typically considered the gold-standard way to study the effectiveness of medical interventions.
To date, there have been no randomised controlled trials of puberty blockers for transgender adolescents, which has led some to label this treatment as experimental. However, conducting such trials of hormonal interventions in transgender youth is problematic, as it would be unethical to withhold treatment for research purposes.
It’s common not to have data from randomised controlled trials in paediatric care more broadly. The use of puberty blockers for early puberty displays similar research gaps.
However, the politicisation of trans young people has seen the use of puberty blockers in transgender adolescents held to a different standard.
How are puberty blockers accessed in different clinical settings?
In the United Kingdom, puberty blockers will now only be accessed by transgender adolescents via the National Health Service (NHS) in a research setting, following the adoption of recommendations by the Cass review, which reviewed gender identity services available to children and young people via the NHS.
One of the main criticisms of the review was it failed to consider the likely harms of denying transgender adolescents hormonal interventions.
In Australia, health experts have also cautioned against comparing our health system to the NHS and highlighted that many of the review’s recommendations align with existing practices within Australian specialist gender services.
Puberty blockers in Australia are accessed by transgender adolescents as part of a comprehensive, team-based approach to gender-affirming care. This emphasises holistic, individualised care which considers the young person’s stage of puberty, while balancing potential benefits and risks.
Sasha Bailey receives research funding from The Matilda Centre for Research in Mental Health and Substance Use, Suicide Prevention Australia, and The Pride Foundation. She is Secretary of the NSW Branch of Public Health Association of Australia, Secretary of GLBTIQ Multicultural Council, and Early Career Member of the Editorial Board of Prevention Science. Sasha currently serves on the ACON Research Ethics Review Committee, Family Planning Australia Research Ethics Committee, and Community Mental Health & Drug and Alcohol Research Network Research Ethics Consultation Committee.
Dr Cristyn Davies receives funding from the Australian Research Council and the Medical Research Future Fund. Dr Davies reports voluntarily being President of the Australian Association for Adolescent Health; co-chair of the Human Rights Council of Australia; co-chair of the Child and Youth Special Interest Group for the Public Health Association of Australia; an ambassador to Twenty10 Incorporating the Gay and Lesbian Counselling Service of New South Wales; and co-chair of the research committee for the Australian Professional Association for Trans Health.
Ken Pang is a paediatrician at the Royal Children's Hospital in Melbourne. He receives research funding from the Australian National Health and Medical Research Council, the Medical Research Future Fund, the Royal Children's Hospital Foundation, and the Hugh D T Williamson Foundation. He is a member of the Australian Professional Association for Trans Health, the World Professional Association for Transgender Health, and the editorial board of the journal, Transgender Health.
Rachel Skinner is a paediatrician at the Sydney Children's Hospitals Network and receives research funding from the National Health and Medical Research Council, the Medical Research Future Fund and the Australian Research Council. She has professional memberships with the Australian Professional Association of Transgender Health and the World Professional Association of Transgender Health.
This article was originally published on The Conversation. Read the original article.
